When esophageal squamous cell carcinoma reaches the metastatic stage, the disease has spread beyond the esophagus to distant organs, profoundly altering how doctors approach care and what patients can expect from treatment.

Fighting Back: How Doctors Approach Metastatic Esophageal Squamous Cell Carcinoma

Metastatic esophageal squamous cell carcinoma represents a significant challenge in modern medicine. At this advanced stage, the cancer has traveled from the esophagus to distant parts of the body, fundamentally changing the goals and methods of treatment. The primary aim of treatment shifts from attempting to cure the disease to controlling symptoms, slowing the cancer’s progression, and helping patients maintain the best possible quality of life for as long as possible^[1].

The approach to managing this condition depends heavily on several factors. Doctors consider where the cancer has spread, how far it has progressed, the patient’s overall health and physical condition, and most importantly, what the patient wants from their care. Every person’s situation is unique, and treatment plans are carefully tailored to match individual circumstances^[2].

Treatment typically involves multiple approaches working together. There are standard treatments that medical societies around the world have approved based on years of research and clinical experience. Additionally, there are newer, experimental therapies being tested in clinical trials—carefully controlled research studies that evaluate promising new drugs and treatment combinations. These trials offer hope for better outcomes and represent the cutting edge of cancer research^[3].

Standard Treatment Options for Advanced Disease

For stage 4 metastatic esophageal squamous cell carcinoma, the standard treatment approach involves several different strategies, each addressing specific aspects of the disease. Because the cancer has spread beyond the esophagus, surgery to remove the tumor is usually not an option. Instead, doctors rely on treatments that can reach cancer cells throughout the body^[9].

Chemotherapy as a Foundation

Chemotherapy uses powerful drugs to kill rapidly dividing cancer cells or slow their growth. For metastatic esophageal squamous cell carcinoma, chemotherapy often forms the backbone of treatment. Various drug combinations have been tested over many years, and doctors select specific regimens based on how well patients can tolerate them and what other treatments are being used^[9].

Common chemotherapy drugs used for this condition include cisplatin and fluorouracil, often given together. Other options include combinations such as cisplatin with capecitabine, carboplatin with paclitaxel, or oxaliplatin with fluorouracil and leucovorin. Each of these drug combinations works by interfering with cancer cells’ ability to grow and divide. Some attack the cancer’s DNA, preventing cells from making copies of themselves. Others disrupt the structure cells need to divide into new cells^[9].

The duration of chemotherapy treatment varies widely. Some patients receive treatment for several months, while others may continue for longer periods if the treatment is working and side effects remain manageable. Doctors regularly monitor how well the chemotherapy is controlling the cancer through imaging tests and blood work^[11].

Side effects from chemotherapy are common and can significantly impact daily life. Patients often experience fatigue, nausea and vomiting, loss of appetite, changes in taste, hair loss, and increased susceptibility to infections because chemotherapy affects the immune system. Some drugs can cause numbness or tingling in the hands and feet, a condition called peripheral neuropathy. Managing these side effects requires close collaboration between patients and their medical teams^[17].

Radiation Therapy for Symptom Control

Radiation therapy uses high-energy beams to damage cancer cells’ DNA, causing them to die. In metastatic esophageal squamous cell carcinoma, radiation is usually not used to try to cure the disease but rather to help manage specific symptoms or problems caused by the cancer^[11].

When combined with chemotherapy, a treatment approach called chemoradiation, the two therapies can work together more effectively than either alone. The chemotherapy makes cancer cells more sensitive to radiation, potentially improving the treatment’s impact. This combination may be used when surgery is not an option but doctors want to try to control the tumor in the esophagus while also addressing disease elsewhere in the body^[9].

Radiation therapy is particularly useful for relieving pain, especially when cancer has spread to bones, or for reducing bleeding from tumors. It can also help when the tumor is blocking the esophagus, making it difficult to swallow. The treatment is typically given five days a week over several weeks, though the exact schedule depends on the goals of treatment^[17].

Side effects from radiation to the chest area can include difficulty swallowing that actually worsens temporarily, fatigue, skin changes in the treatment area that resemble sunburn, and inflammation of the esophagus. These effects usually improve after treatment ends, though some may persist^[17].

Procedures to Improve Swallowing

One of the most distressing symptoms of esophageal cancer is difficulty swallowing, medically known as dysphagia. As the tumor grows, it can block the esophagus, making it hard or impossible to eat solid foods or even drink liquids. Several procedures can help relieve this blockage and improve a patient’s ability to eat and drink^[9].

An esophageal stent is a small tube, usually made of metal mesh, that doctors can place inside the esophagus to keep it open. Using an endoscope—a flexible tube with a camera—doctors guide the stent to the narrowed area and expand it, creating a pathway for food and liquids to pass through. This procedure can provide rapid relief from swallowing difficulties^[9].

Other approaches include esophageal dilation, where doctors gently stretch the narrowed area using special balloons or dilators, and laser surgery, which uses concentrated light beams to burn away tumor tissue blocking the esophagus. Photodynamic therapy combines a special drug that makes cancer cells sensitive to light with laser treatment to destroy tumor tissue^[9].

For patients who cannot swallow enough to maintain nutrition, doctors may recommend placing a feeding tube directly into the stomach. This allows liquid nutrition to bypass the esophagus entirely, helping patients maintain their strength and weight during cancer treatment^[9].

Breakthrough Treatments Being Tested in Clinical Trials

The landscape of treatment for metastatic esophageal squamous cell carcinoma has been transformed in recent years by the development of new therapies that work differently from traditional chemotherapy. These innovative treatments are being carefully studied in clinical trials around the world, offering new hope for patients with this challenging disease^[8].

Immunotherapy: Unleashing the Immune System

Immunotherapy represents one of the most significant advances in cancer treatment in recent decades. Unlike chemotherapy, which directly attacks cancer cells, immunotherapy works by helping the body’s own immune system recognize and destroy cancer cells. Cancer cells often develop ways to hide from the immune system or turn off immune responses. Immunotherapy drugs can remove these disguises and reactivate the immune attack^[8].

The most studied immunotherapy drugs for esophageal squamous cell carcinoma are called checkpoint inhibitors. These drugs block proteins that normally act as brakes on the immune system. When cancer cells use these proteins to avoid immune attack, checkpoint inhibitors release the brakes, allowing immune cells to recognize and attack the tumor^[8].

Pembrolizumab (known by the brand name Keytruda) is one such checkpoint inhibitor that has shown promising results. In clinical trials, pembrolizumab has been tested both alone and in combination with chemotherapy for patients with metastatic esophageal squamous cell carcinoma. Studies have shown that when pembrolizumab is combined with chemotherapy drugs like cisplatin and fluorouracil as the first treatment for metastatic disease, patients may live longer compared to chemotherapy alone^[9].

Another checkpoint inhibitor called nivolumab (Opdivo) has also been studied extensively. Clinical trials have evaluated nivolumab both as a first-line treatment (the first treatment given) and as a second-line treatment (used when the first treatment stops working). Research suggests that nivolumab may be particularly effective in patients whose tumors express certain markers, though it can work in others as well^[9].

The way immunotherapy works means it can cause different side effects compared to chemotherapy. Instead of attacking rapidly dividing cells throughout the body, immunotherapy revs up the immune system, which can sometimes cause it to attack normal tissues. This can lead to inflammation in various organs, causing symptoms such as diarrhea and colitis when the intestines are affected, liver inflammation, lung inflammation causing cough and shortness of breath, or effects on hormone-producing glands like the thyroid. Most of these side effects can be managed with medications that calm the immune system, though they require careful monitoring^[8].

Not all patients respond equally well to immunotherapy. Researchers have discovered that testing tumors for certain markers can help predict who is most likely to benefit. One such marker is PD-L1, a protein that some cancer cells make to protect themselves from immune attack. Tumors with high levels of PD-L1 often respond better to checkpoint inhibitors. In Europe, regulatory authorities have approved immunotherapy for patients whose tumors test positive for PD-L1, measured using scores called tumor proportion score (TPS) and combined positive score (CPS)^[8].

Targeted Therapy: Precision Medicine Approaches

Targeted therapy drugs are designed to attack specific molecular features of cancer cells. Unlike chemotherapy, which affects all rapidly dividing cells, targeted therapies focus on particular proteins or pathways that cancer cells need to survive and grow. For metastatic esophageal cancer, several targeted therapy drugs have been developed, though they are used more commonly for adenocarcinoma tumors, particularly those at the junction where the esophagus meets the stomach^[9].

Ramucirumab (Cyramza) is a monoclonal antibody—a laboratory-made protein that mimics the immune system’s ability to fight disease. Ramucirumab works by blocking a protein called vascular endothelial growth factor (VEGF), which cancer cells use to create new blood vessels. Tumors need blood vessels to bring them oxygen and nutrients to grow. By preventing new blood vessel formation, ramucirumab can starve tumors and slow their growth. This drug is typically given in combination with chemotherapy drug paclitaxel^[9].

Trastuzumab is another monoclonal antibody that targets tumors with high levels of a protein called HER2. Cancer cells with too much HER2 tend to grow more aggressively. Trastuzumab attaches to HER2 proteins on cancer cells and helps slow or stop their growth. Before patients can receive trastuzumab, their tumor must be tested to confirm it has high HER2 levels. This drug is usually combined with chemotherapy^[9].

A newer targeted therapy called zolbetuximab (Vyloy) works by attaching to a protein called Claudin 18.2 on the surface of some esophageal cancer cells. By binding to this protein, zolbetuximab can help stop cancer cell growth. It is being tested in combination with chemotherapy as a first-line treatment for advanced or metastatic esophageal cancer^[9].

Understanding Clinical Trial Phases

New cancer treatments must go through a careful, step-by-step testing process before they can be widely used. This process is divided into phases, each designed to answer specific questions about the treatment^[3].

Phase I trials are the first tests of a new treatment in humans. These small studies, usually involving 15 to 30 patients, focus primarily on safety. Researchers want to understand what dose of the drug is safe, what side effects it causes, and how the body processes the medication. While the main goal is safety, researchers also watch for any signs that the treatment might be working against cancer^[3].

Phase II trials are larger studies that enroll more patients, typically 30 to 100 or more. Once researchers know a treatment is reasonably safe from Phase I, Phase II trials focus on whether the treatment actually works. Does it shrink tumors? Does it help patients live longer? Does it improve symptoms? These trials also continue to monitor side effects^[3].

Phase III trials are large studies that compare the new treatment to the current standard treatment. These trials might include hundreds or even thousands of patients. They are designed to definitively answer whether the new treatment is better than, as good as, or worse than existing treatments. Results from Phase III trials form the basis for drug approval by regulatory agencies^[3].

Who Can Participate in Clinical Trials

Each clinical trial has specific requirements about who can enroll, called eligibility criteria. These criteria are not meant to exclude people unfairly but to ensure patient safety and that the study can answer its scientific questions. Common eligibility factors include the type and stage of cancer, what previous treatments the patient has received, overall health status, how well major organs like the liver and kidneys are functioning, and sometimes the presence of specific molecular markers in the tumor^[3].

Clinical trials for metastatic esophageal squamous cell carcinoma are being conducted in many countries around the world, including the United States, various European nations, and elsewhere. Patients interested in clinical trials should discuss options with their oncologist, who can help identify appropriate studies and facilitate enrollment^[8].

Most common treatment methods

• Chemotherapy
  • Cisplatin combined with fluorouracil or capecitabine
  • Carboplatin combined with paclitaxel
  • Oxaliplatin combined with fluorouracil and leucovorin
  • Epirubicin-based combinations with cisplatin or carboplatin and fluorouracil or capecitabine
  • Docetaxel, oxaliplatin, fluorouracil and leucovorin combination
• Immunotherapy
  • Pembrolizumab (Keytruda) alone or combined with chemotherapy
  • Nivolumab (Opdivo) for first-line or second-line treatment
  • Checkpoint inhibitors targeting PD-1 or PD-L1 proteins
• Targeted therapy
  • Ramucirumab (Cyramza) combined with paclitaxel, targeting VEGF pathways
  • Trastuzumab for HER2-positive tumors, combined with chemotherapy
  • Zolbetuximab (Vyloy) targeting Claudin 18.2 protein
• Radiation therapy
  • External beam radiation to control tumor growth
  • Chemoradiation combining radiation with chemotherapy
  • Palliative radiation for pain relief or to reduce bleeding
• Endoscopic procedures
  • Esophageal stent placement to keep the esophagus open
  • Esophageal dilation using balloons or dilators
  • Laser surgery to remove tumor tissue blocking the esophagus
  • Photodynamic therapy combining light-sensitive drugs with laser treatment
  • Radiofrequency ablation to destroy tumor tissue
  • Feeding tube placement for nutritional support